-
UBS Likes The Tune Of Jazz Pharma's Settlement With Hikma
Thursday, April 6, 2017 - 1:45pm | 510Read More...Jazz Pharmaceuticals plc - Ordinary Shares (NASDAQ: JAZZ) announced on Wednesday it has reached a settlement agreement with Hikma Pharmaceuticals Plc (ADR) (OTC: HKMPY) to resolve a patent litigation related to Xyrem oral solution that has been pending in the U.S. District Court for the...
-
Leerink Presents: Your 2017 Biopharma Catalyst Tracker
Monday, March 20, 2017 - 9:17am | 1119Read More...In its biopharma catalysts tracker released March 1, Leerink termed the year 2017 as a busy one for Neuro and Oncology. The firm highlighted the important catalysts for 2017. Celgene — Multiple Readout In 2017 On Celgene Corporation (NASDAQ: CELG), the firm noted that it has multiple readouts...
-
Jazz Pharma To Evaluate If Generic Xyrem's FDA Waiver Meets Required Legal Conditions
Wednesday, January 18, 2017 - 2:23pm | 500Read More...Jazz Pharmaceuticals plc - Ordinary Shares (NASDAQ: JAZZ) have been on a volatile ride. The Move At time of writing, the company's shares were rallying over 11 percent on roughly 2.6 times the average volume on Wednesday. This represented a reversal in sentiment from the move in after-hours...
-
Jazz Pharma On Track To Report Top-Line, Late-Stage Results Of JZP-110 By December
Tuesday, May 17, 2016 - 4:11pm | 309Read More...Jazz Pharmaceuticals plc - Ordinary Shares (NASDAQ: JAZZ) "is well positioned to deliver a long-term EPS CAGR in at least the mid-to-high teens," according to a note from Piper Jaffray. Analyst David Amsellem noted that earnings growth will come from Xyrem, along with growing...
-
How Much Further Can Jazz Pharmaceuticals Fall?
Wednesday, April 8, 2015 - 4:40pm | 390Read More...The S&P 500 is currently coiling within a common chart pattern known as a triangle. The index isn’t really going up, not really going down. At some point the S&P will break out of that triangle. Some industries are performing well in that coiling-type environment, while others are...
